Bellecapital’s Veracyte VCYT Stock Holding History

Bellecapital’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,561	Closed	-$460K	–	191
2021 Q1	$460K	Hold	8,561	–	–	0.14%	116
2020 Q4	$419K	Buy	+8,561	New	+$397K	0.14%	126

Other funds holding VCYT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellecapital's VCYT Position: Q2 2021 in Review

Bellecapital sold out of Veracyte (VCYT) in Q2 2021, closing a stake of 8,561 shares — an estimated $460K sold.

Bellecapital first reported a position in VCYT in Q4 2020 and held it in 2 quarters. The position peaked at $460K in Q1 2021. 214 funds tracked by Wall St. Rank hold VCYT as of Q2 2021.

Bellecapital reported no remaining Veracyte position as of Q2 2021 after selling out during the quarter.
Bellecapital sold 8,561 Veracyte shares in Q2 2021, an estimated $460K.
Bellecapital first reported a position in Veracyte in Q4 2020 and held it in 2 quarters.
Bellecapital's Veracyte position peaked at $460K in Q1 2021.
214 funds tracked by Wall St. Rank held Veracyte as of Q2 2021.

Based on Bellecapital's 13F filing for Q2 2021, filed 28 Jul 2021.